The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · May 2004
Randomized Controlled Trial Clinical TrialTreatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study.
In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. ⋯ Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.
-
J. Allergy Clin. Immunol. · Jan 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialThe addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results.
Because leukotrienes have potent local effects on cutaneous vasculature, leukotriene antagonists might be effective in the treatment of chronic urticaria. ⋯ The results of this study indicate that only patients with autoimmune (ASST positive) chronic urticaria refractory to H(1)-antagonist monotherapy might benefit from the addition of the leukotriene D(4)-receptor antagonist zafirlukast to their treatment regimen. These results also suggest that routine screening of patients with chronic urticaria with the ASST might be useful in formulating therapeutic algorithms in the management of chronic urticaria.
-
J. Allergy Clin. Immunol. · Nov 2003
Randomized Controlled Trial Multicenter Study Clinical TrialFamily-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program.
Beta2-adrenergic receptor (B2AR) polymorphisms have been associated with a variety of asthma-related phenotypes, but association results have been inconsistent across different studies. ⋯ B2AR variants are associated with spirometric values and bronchodilator responsiveness, but different regions of the gene provide evidence for association with these phenotypes.
-
J. Allergy Clin. Immunol. · Aug 2003
Randomized Controlled Trial Clinical TrialThe effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.
Efalizumab is a humanized IgG(1) mAb against the lymphocyte function antigen-1 (LFA-1) alpha chain, CD11a. Blocking of LFA-1/intercellular adhesion molecule interactions could inhibit asthmatic inflammation by blocking adhesion and activation of LFA-1-positive leukocytes. ⋯ Blocking of LFA-1/intercellular adhesion module interactions by efalizumab inhibits the development of allergen-induced cellular inflammatory responses measured in induced sputum and might attenuate the late asthmatic response. Larger studies are needed to confirm this.
-
J. Allergy Clin. Immunol. · May 2003
Randomized Controlled Trial Clinical TrialAnti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial.
Allergic bronchopulmonary aspergillosis (ABPA) complicates chronic asthma and results from hypersensitivity to the fungus Aspergillus fumigatu s, causing an intense systemic immune response and progressive lung damage. ⋯ Itraconazole treatment of subjects with stable ABPA reduces eosinophilic airway inflammation, systemic immune activation, and exacerbations. These results imply that itraconazole is a potential adjunctive treatment for ABPA.